Attenuation of Severe Generalized Junctional Epidermolysis Bullosa by Systemic Treatment with Gentamicin.
Hammersen J, Neuner A, Wild F, Schneider H.
Dermatology. 2019;235(4):315-322. doi: 10.1159/000499906. Epub 2019 May 27.
PMID:31132778
Somatic correction of junctional epidermolysis bullosa by a highly recombinogenic AAV variant.
Melo SP, Lisowski L, Bashkirova E, Zhen HH, Chu K, Keene DR, Marinkovich MP, Kay MA, Oro AE.
Mol Ther. 2014 Apr;22(4):725-33. doi: 10.1038/mt.2013.290. Epub 2014 Jan 6.
PMID:24390279
Skin microbiome analysis of a junctional epidermolysis bullosa patient treated with genetically modified stem cells.
Dermietzel A, Tosun B, Nguyen M, Wessel K, Rauer L, Neumann AU, Hirsch T; CK‐CARE study group; Traidl-Hoffmann C, Reiger M, Hülpüsch C, Kueckelhaus M.
J Dtsch Dermatol Ges. 2025 Jun 12. doi: 10.1111/ddg.15776. Online ahead of print.
PMID:40509691
Mutational analysis of epidermolysis bullosa in Taiwan by whole-exome sequencing complemented by RNA sequencing: a series of 77 patients.
Tu WT, Hou PC, Chen PC, Chen WR, Huang HY, Wang JY, Huang YT, Wu YH, Su CL, Tang YA, Iwata H, Natsuga K, Chao SC, Sun HS, Tang MJ, Lee JY, McGrath JA, Hsu CK.
Orphanet J Rare Dis. 2022 Dec 28;17(1):451. doi: 10.1186/s13023-022-02605-1.
PMID:36578049
Laminin 5 mutations in junctional epidermolysis bullosa: molecular basis of Herlitz vs. non-Herlitz phenotypes.
Nakano A, Chao SC, Pulkkinen L, Murrell D, Bruckner-Tuderman L, Pfendner E, Uitto J.
Hum Genet. 2002 Jan;110(1):41-51. doi: 10.1007/s00439-001-0630-1. Epub 2001 Nov 13.
PMID:11810295
Protein therapeutics for junctional epidermolysis bullosa: incorporation of recombinant beta3 chain into laminin 332 in beta3-/- keratinocytes in vitro.